Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company focused on developing innovative genetic therapies aimed at transforming the lives of patients battling rare and debilitating diseases. Its advanced product portfolio includes three ophthalmology development programs addressing two specific targets. These encompass treatments for X-linked retinitis pigmentosa and achromatopsia, both currently undergoing Phase 1/2 clinical trials. Additionally, an optogenetic therapy candidate is in development to tackle advanced retinal conditions. Beyond its ophthalmic initiatives, AGTC is advancing several preclinical programs. These early-stage endeavors include a program for otology (ear disorders), another for dry age-related macular degeneration, and two targeting central nervous system disorders like frontotemporal dementia and amyotrophic lateral sclerosis. The company maintains strategic partnerships with entities such as the University of Florida, Bionic Sight, Inc., and Otonomy, Inc. Founded in 1999, AGTC's operations are based out of its headquarters in Alachua, Florida.